Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis

Retreatment of tuberculosis involves the management of entities as diverse as relapse, failure, treatment after default, and poor patient adherence to the previous treatment. The emergence of conditions for selection of resistance (failure and partial abandonment) is a matter of great concern. The current chemotherapy is the primary interventions, but the long-term drug combination therapy often leads to adverse reactions. The purpose of this study that is to exploring the role of Chinese medicine Qinbudan on Patients who are initially sputum smear positive or culture-positive who have been treated previously for pulmonary tuberculosis.

Inclusion criteria

• Patients who are initially sputum smear positive (at least two smears as "1+" or at least have a smear as "2+" and above) or culture-positive for pulmonary tuberculosis who have been treated previously
• Aged 18 -65 years of age
• Patients who are willing to give written informed consent

Exclusion criteria

• Participation in another clinical trial 1 month prior to study entry
• Female patients in lactation period, pregnancy or planning to get pregnant during the trial
• Patients who are allergic to the therapeutic medicine
• Patients with severe primary diseases such as cancer, cardiovascular system, digestive system, kidney and hematopoietic system diseases
• Patients co-infected with HIV, hepatitis B or hepatitis C
• Patients with mental illness, acrasia
• Abnormal liver function or combined with other underlying liver disease (fatty liver, alcoholic liver)
• Patients with diabetes, Plasma glucose poorly controlled undertaking
• Patients with auditory dysfunction